LENZ Therapeutics (NASDAQ:LENZ) Coverage Initiated at William Blair

Research analysts at William Blair started coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set an “outperform” rating on the stock.

LENZ has been the subject of a number of other reports. Piper Sandler assumed coverage on shares of LENZ Therapeutics in a report on Wednesday, March 27th. They issued an “overweight” rating and a $28.00 price objective for the company. Citigroup assumed coverage on shares of LENZ Therapeutics in a report on Wednesday, April 10th. They issued a “buy” rating and a $34.00 price objective for the company.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock opened at $19.92 on Monday. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82. The company has a market cap of $165.73 million, a price-to-earnings ratio of -1.28 and a beta of 0.20.

Insider Activity at LENZ Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 998,009 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was bought at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the acquisition, the director now directly owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 38.40% of the stock is currently owned by company insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.